Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for the Study of Diabetes.

Diabetologia. 2009 Jan;52(1):17-30. doi: 10.1007/s00125-008-1157-y. Epub 2008 Oct 22.

PMID:
18941734
2.

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes.

Diabetes Care. 2009 Jan;32(1):193-203. doi: 10.2337/dc08-9025. Epub 2008 Oct 22.

3.

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B; Professional Practice Committee, American Diabetes Association; European Association for the Study of Diabetes.

Diabetologia. 2006 Aug;49(8):1711-21. No abstract available.

PMID:
16802130
4.

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B.

Diabetes Care. 2006 Aug;29(8):1963-72. No abstract available. Erratum in: Diabetes Care. 2006 Nov;49(11):2816-8.

PMID:
16873813
5.

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.

Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS.

Endocr Pract. 2009 Sep-Oct;15(6):540-59. Erratum in: Endocr Pract. 2009 Nov-Dec;15(7):768-70.

PMID:
19858063
7.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
8.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
9.

Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus.

Blonde L.

Am J Med. 2010 Mar;123(3 Suppl):S12-8. doi: 10.1016/j.amjmed.2009.12.005. Review.

PMID:
20206727
10.

Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.

Krentz A.

Diabetes Metab Res Rev. 2009 Feb;25(2):112-26. doi: 10.1002/dmrr.937. Review.

PMID:
19219860
11.

Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs.

LaSalle JR.

Postgrad Med. 2010 Jan;122(1):144-52. doi: 10.3810/pgm.2010.01.2108. Review.

PMID:
20107298
12.

The pharmacological treatment of hyperglycemia in NIDDM. American Diabetes Association.

[No authors listed]

Diabetes Care. 1995 Nov;18(11):1510-8. Review. No abstract available.

PMID:
8722084
13.

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R; American Heart Association; American Diabetes Association.

Circulation. 2003 Dec 9;108(23):2941-8. Review. No abstract available.

14.

Metabolic side effects of antipsychotics: focus on hyperglycemia and diabetes.

Buse JB.

J Clin Psychiatry. 2002;63 Suppl 4:37-41. Review.

PMID:
11913675
15.

Optimal management of type 2 diabetes: the evidence.

Colagiuri S.

Diabetes Obes Metab. 2012 Jan;14 Suppl 1:3-8. doi: 10.1111/j.1463-1326.2011.01506.x. Review.

PMID:
22118704
16.

Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus.

Giugliano D, Ceriello A, Razzoli E, Esposito K.

Clin Drug Investig. 2008;28(4):199-210. Review.

PMID:
18345710
17.

Treating hyperglycemia in type 2 diabetes: new goals and strategies.

Lebovitz HE.

Cleve Clin J Med. 2002 Oct;69(10):809-20. Review.

PMID:
12371804
18.
19.

Treatment of type 2 diabetes in Latin America: a consensus statement by the medical associations of 17 Latin American countries. Latin American Diabetes Association.

Guzmán JR, Lyra R, Aguilar-Salinas CA, Cavalcanti S, Escaño F, Tambasia M, Duarte E; ALAD Consensus Group.

Rev Panam Salud Publica. 2010 Dec;28(6):463-71.

20.

Treatment of type 2 diabetes mellitus: pharmacologic intervention.

McCormick M, Quinn L.

J Cardiovasc Nurs. 2002 Jan;16(2):55-67. Review.

PMID:
11800068
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk